Observational Study of Survival Outcomes of Stage IV Cancer Patients
NCT ID: NCT01843985
Last Updated: 2013-05-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
120 participants
OBSERVATIONAL
2013-06-30
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Randomized Study of Concurrent Chemo-radiotherapy vs Radiotherapy Alone to Local-advanced Small Cell Lung Cancer (SCLC)
NCT01745445
Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage ⅣAB Nasopharyngeal Carcinoma
NCT00816816
Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients
NCT03489616
Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%
NCT03351842
High Dose Radiation Therapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer
NCT03598517
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1. Eligible RCT/Elect RCT
Eligible for regular chemotherapy, elects and receives regular chemotherapy
No interventions assigned to this group
2. Eligible RCT/Elect LDC
Eligible for regular chemotherapy, elects and receives low-dose chemotherapy
No interventions assigned to this group
3. Eligible RCT/Elect PCO
Eligible for regular chemotherapy, elects and receives palliative care only
No interventions assigned to this group
4. Ineligible RCT/Elect LDC
Ineligible for regular chemotherapy, elects and receives low-dose chemotherapy
No interventions assigned to this group
5. Ineligible RCT/Elect PCO
Ineligible for regular chemotherapy, elects and receives palliative care only
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cure Cancer Worldwide Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yang Ling Demonstration Zone Hospital
Yangling, Shaanxi, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YLDZH-OS-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.